Margaret A. Knowles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Margaret A. Knowles has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
Carolyn D. Hurst
Section of Molecular Oncology, Leeds Institute of Cancer and Pathology, St James's University Hospital, Leeds, United Kingdom
13 shared publicationsFiona M. Platt
Division of Molecular Medicine, Leeds Institute of Medical Research at St James's, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK
11 shared publications- Erica di Martino
Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
7 shared publications - Gavin Kelly
Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK
7 shared publications - Chaohua Zhang6 shared publications
Claire F. Taylor
Cancer Research UK Leeds Centre, Leeds Institute of Cancer and Pathology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK
6 shared publications
Latest Publications
- 1 January 2024
- Published by Springer Nature
- p. 519-522
Future Directions in Bladder Cancer Research and Clinical Implications
- 1 January 2024
- Published by Springer Nature
- p. 519-522
Future Directions in Bladder Cancer Research and Clinical Implications
- Top Cited Papers
- 26 October 2023
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 9 (1) , 1-21
Bladder cancer
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is non-muscle invasive or muscle invasive. The mutational burden is higher in muscle-invasive than in non-muscle-invasive disease. Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification. Subtyping of both forms of bladder cancer is likely to change considerably with the advent of single-cell analysis methods. Early detection signifies a better disease prognosis; thus, minimally invasive diagnostic options are needed to improve patient outcomes. Urine-based tests are available for disease diagnosis and surveillance, and analysis of blood-based cell-free DNA is a promising tool for the detection of minimal residual disease and metastatic relapse. Transurethral resection is the cornerstone treatment for non-muscle-invasive bladder cancer and intravesical therapy can further improve oncological outcomes. For muscle-invasive bladder cancer, radical cystectomy with neoadjuvant chemotherapy is the standard of care with evidence supporting trimodality therapy. Immune-checkpoint inhibitors have demonstrated benefit in non-muscle-invasive, muscle-invasive and metastatic bladder cancer. Effective management requires a multidisciplinary approach that considers patient characteristics and molecular disease characteristics.
- 26 October 2023
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 9 (1) , 1-21
Top Cited PapersBladder cancer
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is non-muscle invasive or muscle invasive. The mutational burden is higher in muscle-invasive than in non-muscle-invasive disease. Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification. Subtyping of both forms of bladder cancer is likely to change considerably with the advent of single-cell analysis methods. Early detection signifies a better disease prognosis; thus, minimally invasive diagnostic options are needed to improve patient outcomes. Urine-based tests are available for disease diagnosis and surveillance, and analysis of blood-based cell-free DNA is a promising tool for the detection of minimal residual disease and metastatic relapse. Transurethral resection is the cornerstone treatment for non-muscle-invasive bladder cancer and intravesical therapy can further improve oncological outcomes. For muscle-invasive bladder cancer, radical cystectomy with neoadjuvant chemotherapy is the standard of care with evidence supporting trimodality therapy. Immune-checkpoint inhibitors have demonstrated benefit in non-muscle-invasive, muscle-invasive and metastatic bladder cancer. Effective management requires a multidisciplinary approach that considers patient characteristics and molecular disease characteristics.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Alteration of Cell–Cell and Cell–Matrix Adhesion in Urothelial Cells: An Oncogenic Mechanism for Mutant FGFR3
Supplementary Figure 1. TACSTD1 protein expression in normal bladder (A) and pTaG2 tumours (B, C); HAS3 protein expression in normal bladder (D) and pTaG2 tumours (E, F). Original magnification x400. Horizontal bar indicates 20 µm.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Alteration of Cell–Cell and Cell–Matrix Adhesion in Urothelial Cells: An Oncogenic Mechanism for Mutant FGFR3
Supplementary Figure 1. TACSTD1 protein expression in normal bladder (A) and pTaG2 tumours (B, C); HAS3 protein expression in normal bladder (D) and pTaG2 tumours (E, F). Original magnification x400. Horizontal bar indicates 20 µm.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Alteration of Cell–Cell and Cell–Matrix Adhesion in Urothelial Cells: An Oncogenic Mechanism for Mutant FGFR3
Supplementary Table 1. Clinico-pathological characteristics and FGFR3 mutation status of the tumours used for the mRNA study
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Alteration of Cell–Cell and Cell–Matrix Adhesion in Urothelial Cells: An Oncogenic Mechanism for Mutant FGFR3
Supplementary Table 1. Clinico-pathological characteristics and FGFR3 mutation status of the tumours used for the mRNA study